Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia.

Item

http://www.wikidata.org/entity/Q43175147

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia.

@en

Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia.

@nl

type

Item

label

Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia.

@en

Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia.

@nl

prefLabel

Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia.

@en

Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia.

@nl

P1476

Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia.

@en

P2093

Andrea Biondi

http://www.w3.org/2001/XMLSchema#string

Veronica Leoni

http://www.w3.org/2001/XMLSchema#string

P2860

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias.

Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International

Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial

Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab.

First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia.

The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission

Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005.

Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031.

Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia.

Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study

P304

295-299

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.3324/HAEMATOL.2015.124016

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

100

http://www.w3.org/2001/XMLSchema#string

P577

2015-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

273155167

http://www.w3.org/2001/XMLSchema#string

P698

25740105

http://www.w3.org/2001/XMLSchema#string

P921

leukemia

P932

4349266

http://www.w3.org/2001/XMLSchema#string